Pulse Biosciences (NASDAQ: PLSE) releases updated March 2026 investor deck

Rhea-AI Filing Summary

Pulse Biosciences, Inc. furnished an updated investor presentation dated March 2026, which has been posted on its website and attached as Exhibit 99.1. The deck includes summary financial information, details on the next-generation nPulse cardiac catheter under development, and an increased focus on EP cardio ablation products and clinical development following what it describes as unprecedented clinical outcomes data from its EU feasibility study.

The company plans to use this investor presentation, in whole or in part and potentially with modifications, in meetings with investors, analysts, and others. The information is provided under a Reg FD disclosure, is considered "furnished" rather than "filed," and includes forward-looking statements that are subject to risks and uncertainties referenced in the company’s SEC filings.

false 0001625101 0001625101 2026-03-03 2026-03-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 3, 2026

Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware	001-37744	46-5696597
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
(Address of Principal Executive Offices) (Zip Code)
510-906-4600
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share	PLSE	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On March 3, 2026, Pulse Biosciences, Inc., a Delaware corporation (the “Company”), posted an updated investor presentation on its website. The updated investor presentation (the “Investor Deck”) discloses, among other things, certain summary financial information for the Company, a description of its next generation nPulse cardiac catheter under development, as well as strengthened "focus on EP cardio ablation product and clinical development following unprecedented clinical outcomes data in . . . [the Company's] EU feasibility study." The Company expects to use this updated investor presentation, either in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. A copy of the Investor Deck is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. The Investor Deck is also available on the Company’s website at www.pulsebiosciences.com under “Investors.”

Except for the Investor Deck, information contained on, or accessible through, the Company’s website is not a part of, and is not incorporated by reference in, this Current Report on Form 8-K. The information contained in the Investor Deck itself is summary information only and it contains forward looking statements that are subject to risks and uncertainties, including those set forth in the Company’s filings with the U.S. Securities and Exchange Commission. Also, the information in the Investor Deck is as of March 2026, and the Company undertakes no obligation to publicly update or revise the information contained in the Investor Deck or this Item 7.01, except as required by law, although it made do so from time to time.

The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly stated otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Investor Deck, dated March 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PULSE BIOSCIENCES, INC.
Date: March 3, 2026	By:	/s/ Paul A. LaViolette
		Paul A. LaViolette
		Chief Executive Officer (Principal Executive Officer)

Exhibit 99.1 - Investor Presentation March 2026

FAQ

What did Pulse Biosciences (PLSE) disclose in its latest 8-K filing?

Pulse Biosciences disclosed that it furnished an updated March 2026 investor presentation. The deck includes summary financial information, highlights development of its next-generation nPulse cardiac catheter, and emphasizes a stronger focus on EP cardio ablation following unprecedented outcomes in an EU feasibility study.

What is included in Pulse Biosciences’ March 2026 investor presentation?

The March 2026 investor presentation includes summary financial information and a description of Pulse Biosciences’ next-generation nPulse cardiac catheter under development. It also outlines a strengthened focus on EP cardio ablation products and clinical development after unprecedented clinical outcomes in the company’s EU feasibility study.

How will Pulse Biosciences (PLSE) use the updated investor deck?

Pulse Biosciences expects to use the updated investor deck, in whole or in part and possibly with modifications, in presentations to investors, analysts, and others. This makes the deck a key communication tool for explaining its technology, financial summary information, and strategic clinical focus.

Where can investors access Pulse Biosciences’ new investor presentation?

Investors can access Pulse Biosciences’ updated March 2026 investor presentation as Exhibit 99.1 to the 8-K and on the company’s website at www.pulsebiosciences.com under “Investors.” The filing specifies that, aside from the deck, website information is not incorporated by reference.

Does the Pulse Biosciences investor deck contain forward-looking statements?

Yes. The company states that the investor deck contains forward-looking statements subject to risks and uncertainties. These risks include those described in Pulse Biosciences’ SEC filings, and the company does not undertake to update the information in the deck or the related disclosure except as required by law.

Is Pulse Biosciences’ March 2026 investor deck considered filed with the SEC?

No. The company specifies that the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, for purposes of Section 18 of the Exchange Act. As a result, it is not automatically subject to Section 18 liabilities or incorporated into other SEC filings unless expressly stated.

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 - INVESTOR PRESENTATION MARCH 2026 10.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.2 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.3 KB